Fig. 1. Prevalence of hyperkalemia and use of angiotensin II receptor blockades (ARBs) in Korean patients with chronic kidney disease (CKD). (A) Percentages of patients with hyperkalemia (>5.5 mmol/L) from CKD stage 1 through 5. (B) Percentages of patients taking ARBs from CKD stage 1 through 5. Data were produced from the KNOW-CKD cohort and offered by Drs. Eunjeong Kang and Kook-Hwan Oh.